- ISIN
- US03615A1088
- CUSIP
- 03615A108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 12, 2010
Highlights
- Market Cap
- $34.43M
- Enterprise Value
- -$14.18B
- EPS (TTM)
- -$731.06
- EBITDA (TTM)
- -$23.24M
- Year Range
- $1.54 - $5.50
- Target Price
- $25.67
- ROA (TTM)
- -108.53%
- ROE (TTM)
- -563.96%
- Avg. Volume (1M)
- 794K
- Avg. Volume Value (1M)
- $1.44M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ANVS Performance Chart
Annovis Bio, Inc. (ANVS) is down 49.4% since the beginning of the year. At $2 per share, ANVS is trading 68.2% below its 52-week high of $6. Investors who bought $1,000 worth of ANVS shares 5 years ago would now be looking at an investment worth $51.
Loading charts...
Compare this symbol against anything
Returns By Period
Annovis Bio, Inc. (ANVS) has returned -49.42% so far this year and -30.28% over the past 12 months.
Annovis Bio, Inc.
- 1D
- -1.13%
- 1M
- -9.33%
- 6M
- -35.19%
- YTD
- -49.42%
- 1Y
- -30.28%
- 3Y*
- -49.43%
- 5Y*
- -44.89%
- 10Y*
- —
- ALL TIME*
- -18.52%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ANVS Monthly Returns History
Based on dividend-adjusted daily data since Jan 29, 2020, ANVS's average daily return is +0.23%, while the average monthly return is +4.14%. At this rate, an investment would double in approximately 1.4 years.
Historically, 38% of months were positive and 62% were negative. The best month was Feb 2021 with a return of +156.2%, while the worst month was Feb 2025 at -62.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, ANVS closed higher 47% of trading days. The best single day was May 21, 2021 with a return of +127.3%, while the worst single day was Jul 29, 2021 at -60.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.97% | -0.74% | -16.79% | -11.66% | -2.54% | -3.13% | -5.91% | -49.42% | |||||
| 2025 | -3.18% | -62.42% | -18.03% | -0.67% | 57.72% | -7.66% | 25.81% | -15.38% | -10.39% | 1.45% | 142.86% | -32.16% | -31.21% |
| 2024 | -40.91% | -23.35% | 40.50% | -53.19% | 17.59% | -12.06% | 61.63% | -9.13% | -4.73% | 15.14% | -27.69% | -25.04% | -73.10% |
| 2023 | 23.01% | 3.57% | -9.94% | -5.45% | -10.09% | 9.08% | -3.50% | -10.08% | -23.47% | -30.35% | 28.44% | 120.26% | 39.24% |
| 2022 | -13.71% | -6.39% | -5.99% | -29.29% | -2.75% | 23.53% | 1.41% | 0.87% | 18.10% | -8.39% | 7.09% | -0.07% | -23.61% |
| 2021 | 32.36% | 156.21% | 9.11% | -20.65% | 103.70% | 89.76% | -59.77% | 9.61% | -15.87% | -16.47% | -9.28% | -26.93% | 133.16% |
Benchmark Metrics
Annovis Bio, Inc. has an annualized alpha of 50.18%, beta of 1.21, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 29, 2020.
- This stock participated in 219.66% of S&P 500 Index downside but only 180.28% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 50.18%
- Beta
- 1.21
- R²
- 0.04
- Upside Capture
- 180.28%
- Downside Capture
- 219.66%
Return for Risk
Risk / Return Rank
ANVS ranks 28 for risk / return — above 28% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Annovis Bio, Inc. (ANVS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ANVS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.81 | ||
| Sortino ratioReturn per unit of downside risk | -2.03 | ||
| Omega ratioGain probability vs. loss probability | 0.99 | 1.25 | -0.26 |
| Calmar ratioReturn relative to maximum drawdown | -0.52 | 2.00 | -2.53 |
| Martin ratioReturn relative to average drawdown | -0.80 | 8.49 | -9.29 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Annovis Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Annovis Bio, Inc. was 98.99%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Annovis Bio, Inc. drawdown is 98.55%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.99%Apr 2025 | 3y 8mo | — | 5y 21dJul 2021 - now | 2025 selloff2025 |
-73.93%Apr 2020 | 2mo 3d | 9mo 16d | 11mo 19dJan 2020 - Jan 2021 | COVID crash2020 |
-43.94%Apr 2021 | 29d | 1mo 5d | 2mo 4dMar 2021 - May 2021 | — |
-25.67%May 2021 | 3d | 7d | 10dMay 2021 - Jun 2021 | — |
-25.05%Mar 2021 | 10d | 10d | 20dFeb 2021 - Mar 2021 | — |
Drawdown Indicators
| ANVS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.99% | -56.78% | -42.21% |
Max Drawdown (1Y)Largest decline over 1 year | -68.82% | -9.10% | -59.72% |
Max Drawdown (3Y)Largest decline over 3 years | -93.78% | -18.90% | -74.88% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -25.43% | -71.70% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.55% | -1.58% | -96.97% |
Average DrawdownAverage peak-to-trough decline | -78.61% | -10.70% | -67.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 45.13% | 2.14% | +42.99% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Annovis Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Annovis Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ANVS in comparison with other companies in the Biotechnology industry. Currently, ANVS has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ANVS
Add Annovis Bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ANVS